Luis Bobadilla - Grifols SA Independent Director
GRFS Stock | USD 6.48 0.18 2.86% |
Director
Mr. Luis Isasi Fernandez de Bobadilla serves as Independent Director of Grifols, S.A. since May 24, 2011. He also acts as Managing Director of Morgan Stanley Espana, Country Head for Spanish Operations and Board Member of the Madrid Stock Exchange. He joined Morgan Stanley in London in 1987. Previously, he served as Executive Director of First Chicago Ltd in London, and prior to that, he worked at the Latin American Department of Morgan Guaranty Trust Co in New York. He started his professional career in Abengoa, where he joined in 1977. He holds a Bachelors degree in Economic and Business Sciences, both from Universidad de Sevilla and a Masters degree in Business Administration from the Columbia University in 1982. since 2011.
Tenure | 13 years |
Address | Avinguda de la Generalitat, 152, Barcelona, Spain, 08174 |
Phone | 34 935 712 200 |
Web | https://www.grifols.com |
Grifols SA Management Efficiency
The company has return on total asset (ROA) of 0.0214 % which means that it generated a profit of $0.0214 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.022 %, meaning that it created $0.022 on every $100 dollars invested by stockholders. Grifols SA's management efficiency ratios could be used to measure how well Grifols SA manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to 0 in 2024. Return On Capital Employed is likely to drop to 0.04 in 2024. At this time, Grifols SA's Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 15.8 B in 2024, whereas Net Tangible Assets are likely to drop (2.1 B) in 2024.Similar Executives
Showing other executives | DIRECTOR Age | ||
Cornelia Bargmann | AstraZeneca PLC ADR | N/A | |
Rebecca Henderson | Amgen Inc | 57 | |
Harry Dietz | GlaxoSmithKline PLC ADR | 62 | |
Harish Manwani | Gilead Sciences | 64 | |
Richard Mulligan | Biogen Inc | 62 | |
JeanRene Fourtou | Sanofi ADR | 75 | |
Lynn Elsenhans | GlaxoSmithKline PLC ADR | 64 | |
Patricia Russo | Merck Company | 68 | |
Stephanie Burns | GlaxoSmithKline PLC ADR | 60 | |
Ann Cairns | AstraZeneca PLC ADR | 57 | |
Gerard Kemmel | Sanofi ADR | 74 | |
Christophe Babule | Sanofi ADR | N/A | |
Klaus Pohle | Sanofi ADR | 76 | |
John Noseworthy | Merck Company | 66 | |
Brian Posner | Biogen Inc | 56 | |
Philip Broadley | AstraZeneca PLC ADR | 52 | |
Togo West | Bristol Myers Squibb | 72 | |
Robert Williams | Amgen Inc | 69 | |
Srikant Datar | Novartis AG ADR | 67 | |
Claudia Dyckerhoff | Roche Holding Ltd | 51 | |
Genevieve Berger | AstraZeneca PLC ADR | 64 |
Management Performance
Return On Equity | 0.022 | ||||
Return On Asset | 0.0214 |
Grifols SA ADR Leadership Team
Elected by the shareholders, the Grifols SA's board of directors comprises two types of representatives: Grifols SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Grifols. The board's role is to monitor Grifols SA's management team and ensure that shareholders' interests are well served. Grifols SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Grifols SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
Antonio Pares, Director of Planning and Control | ||
Alberto Roura, President Division | ||
Carsten Schroeder, President Of The Diagnostic Division | ||
Albert Roura, CEO of Laboratorios Grifols SA | ||
Lafmin Morgan, President Of The Bioscience And Hospital Division | ||
Juan Roura, Vice President of Production, Executive Director | ||
Eva Tubau, Chief Scientific Officer | ||
Anna Lluch, Independent Director | ||
Carlos Fernandez, Deputy Industrial Vice President | ||
Jose Gras, Director, Representative of Thorthol Holdings BV | ||
Maria Llano, Chief Officer | ||
Edgar Jannotta, Independent Director | ||
Vicente Torre, Chief Officer | ||
Nacho Abia, CEO Director | ||
Mateo Humbert, Director of Human Resources | ||
Montserrat Calvo, Chief Administrative Officer, Controller | ||
Montserrat Llamas, Chief Officer | ||
Ramon Roca, Vice-President of Marketing and Sales and Executive Director | ||
Vctor Deu, CoCEO Director | ||
David Bell, Vice President of Corporate Operations and Development of Grifols Inc and United States Subsidiaries | ||
Victor Deu, Co-CEO, Executive Director | ||
Luis Bobadilla, Independent Director | ||
Inigo Mardones, Director | ||
Thomas Glanzmann, Executive Chairman | ||
Carina Lazaro, Independent Director | ||
Joel Abelson, President of North America Commercial Division of Grifols Inc | ||
Steven Mayer, Director | ||
Javier Ribes, CEO of Instituto Grifols SA | ||
Alfredo Guerra, CFO and Corporate VP | ||
Raimon Roura, Non-Member Secretary of the Board | ||
Victor Roura, Chairman, CEO and President and Member of Appointments and Remuneration Committee | ||
Brett Ingersoll, Director | ||
Shinji Wada, President of Plasma Centers of Grifols Inc | ||
Tomas Gelabert, Director | ||
Nuria Lapea, Risk Treasury | ||
Sergio Adell, President Support | ||
M Tubau, Corporate Affairs | ||
Steven JD, Ex Chairman | ||
Marla Salmon, Independent Director | ||
Nuria Barnes, Non-Member Assistant Secretary of the Board | ||
Gregory Rich, President of Grifols Inc and Subsidiaries in the US | ||
Belen Morenes, Independent Director | ||
Nuria Lapena, Director of Shareholder and Investor Relations |
Grifols Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Grifols SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.022 | ||||
Return On Asset | 0.0214 | ||||
Profit Margin | 0.01 % | ||||
Operating Margin | 0.13 % | ||||
Current Valuation | 16.43 B | ||||
Shares Outstanding | 679.09 M | ||||
Shares Owned By Institutions | 49.84 % | ||||
Number Of Shares Shorted | 5.97 M | ||||
Price To Earning | 14.34 X | ||||
Price To Book | 0.71 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Grifols SA ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census. Note that the Grifols SA ADR information on this page should be used as a complementary analysis to other Grifols SA's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Complementary Tools for Grifols Stock analysis
When running Grifols SA's price analysis, check to measure Grifols SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Grifols SA is operating at the current time. Most of Grifols SA's value examination focuses on studying past and present price action to predict the probability of Grifols SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Grifols SA's price. Additionally, you may evaluate how the addition of Grifols SA to your portfolios can decrease your overall portfolio volatility.
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Grifols SA's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Grifols SA. If investors know Grifols will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Grifols SA listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.787 | Earnings Share 0.1 | Revenue Per Share 4.849 | Quarterly Revenue Growth 0.033 | Return On Assets 0.0214 |
The market value of Grifols SA ADR is measured differently than its book value, which is the value of Grifols that is recorded on the company's balance sheet. Investors also form their own opinion of Grifols SA's value that differs from its market value or its book value, called intrinsic value, which is Grifols SA's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Grifols SA's market value can be influenced by many factors that don't directly affect Grifols SA's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Grifols SA's value and its price as these two are different measures arrived at by different means. Investors typically determine if Grifols SA is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Grifols SA's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.